103 related articles for article (PubMed ID: 22269645)
1. Lactoferricin but not lactoferrin inhibit herpes simplex virus type 2 infection in mice.
Shestakov A; Jenssen H; Nordström I; Eriksson K
Antiviral Res; 2012 Mar; 93(3):340-5. PubMed ID: 22269645
[TBL] [Abstract][Full Text] [Related]
2. 3-Hydroxyphthaloyl beta-lactoglobulin. IV Antiviral activity in the mouse model of genital herpesvirus infection.
Kokuba H; Aurelian L; Neurath AR
Antivir Chem Chemother; 1998 Jul; 9(4):353-7. PubMed ID: 9875414
[TBL] [Abstract][Full Text] [Related]
3. Effect of resveratrol on herpes simplex virus vaginal infection in the mouse.
Docherty JJ; Fu MM; Hah JM; Sweet TJ; Faith SA; Booth T
Antiviral Res; 2005 Sep; 67(3):155-62. PubMed ID: 16125258
[TBL] [Abstract][Full Text] [Related]
4. Synthetic analogues of bovine bactenecin dodecapeptide reduce herpes simplex virus type 2 infectivity in mice.
Shestakov A; Jenssen H; Hancock RE; Nordström I; Eriksson K
Antiviral Res; 2013 Nov; 100(2):455-9. PubMed ID: 24012999
[TBL] [Abstract][Full Text] [Related]
5. Glycosaminoglycans are not indispensable for the anti-herpes simplex virus type 2 activity of lactoferrin.
Marchetti M; Ammendolia MG; Superti F
Biochimie; 2009 Jan; 91(1):155-9. PubMed ID: 18534197
[TBL] [Abstract][Full Text] [Related]
6. The anti-papillomavirus activity of human and bovine lactoferricin.
Mistry N; Drobni P; Näslund J; Sunkari VG; Jenssen H; Evander M
Antiviral Res; 2007 Sep; 75(3):258-65. PubMed ID: 17481742
[TBL] [Abstract][Full Text] [Related]
7. An improved system for the evaluation of antiviral compounds against herpes simplex virus type 2.
Yin S; Li Y; Xia H; Zhao J; Zhang Z; Tang S; Kou Z; Chen J; Yu J; Fan Z; Li T
J Virol Methods; 2013 May; 189(2):317-20. PubMed ID: 23454799
[TBL] [Abstract][Full Text] [Related]
8. Estradiol regulates susceptibility following primary exposure to genital herpes simplex virus type 2, while progesterone induces inflammation.
Gillgrass AE; Fernandez SA; Rosenthal KL; Kaushic C
J Virol; 2005 Mar; 79(5):3107-16. PubMed ID: 15709030
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of HSV cell-to-cell spread by lactoferrin and lactoferricin.
Jenssen H; Sandvik K; Andersen JH; Hancock RE; Gutteberg TJ
Antiviral Res; 2008 Sep; 79(3):192-8. PubMed ID: 18456345
[TBL] [Abstract][Full Text] [Related]
10. Rectal immunization generates protective immunity in the female genital tract against herpes simplex virus type 2 infection: relative importance of myeloid differentiation factor 88.
Tengvall S; O'Hagan D; Harandi AM
Antiviral Res; 2008 Jun; 78(3):202-14. PubMed ID: 18276020
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility of human female primary genital epithelial cells to herpes simplex virus, type-2 and the effect of TLR3 ligand and sex hormones on infection.
MacDonald EM; Savoy A; Gillgrass A; Fernandez S; Smieja M; Rosenthal KL; Ashkar AA; Kaushic C
Biol Reprod; 2007 Dec; 77(6):1049-59. PubMed ID: 17881767
[TBL] [Abstract][Full Text] [Related]
12. A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2.
Parr MB; Kepple L; McDermott MR; Drew MD; Bozzola JJ; Parr EL
Lab Invest; 1994 Mar; 70(3):369-80. PubMed ID: 8145530
[TBL] [Abstract][Full Text] [Related]
13. Observations on recovery from and recurrence of HSV-2 infections in adult mice that were rescued from lethal vaginal infection by antiviral therapy.
Parr EL; Holliday EM; Collard MW; Parr MB
Arch Virol; 2005 Sep; 150(9):1885-902. PubMed ID: 15824886
[TBL] [Abstract][Full Text] [Related]
14. Topical application of polyethylenimine as a candidate for novel prophylactic therapeutics against genital herpes caused by herpes simplex virus.
Hayashi K; Onoue H; Sasaki K; Lee JB; Kumar PK; Gopinath SC; Maitani Y; Kai T; Hayashi T
Arch Virol; 2014 Mar; 159(3):425-35. PubMed ID: 24046087
[TBL] [Abstract][Full Text] [Related]
15. An immunomodulating dipeptide, SCV-07, is a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2).
Rose WA; Tuthill C; Pyles RB
Int J Antimicrob Agents; 2008 Sep; 32(3):262-6. PubMed ID: 18619817
[TBL] [Abstract][Full Text] [Related]
16. Protective effect of a natural carrageenan on genital herpes simplex virus infection in mice.
Carlucci MJ; Scolaro LA; Noseda MD; Cerezo AS; Damonte EB
Antiviral Res; 2004 Nov; 64(2):137-41. PubMed ID: 15498610
[TBL] [Abstract][Full Text] [Related]
17. Quantification of poly(I:C)-mediated protection against genital herpes simplex virus type 2 infection.
Herbst-Kralovetz MM; Pyles RB
J Virol; 2006 Oct; 80(20):9988-97. PubMed ID: 17005677
[TBL] [Abstract][Full Text] [Related]
18. The effect of daily valacyclovir suppression on herpes simplex virus type 2 viral shedding in HSV-2 seropositive subjects without a history of genital herpes.
Sperling RS; Fife KH; Warren TJ; Dix LP; Brennan CA
Sex Transm Dis; 2008 Mar; 35(3):286-90. PubMed ID: 18157071
[TBL] [Abstract][Full Text] [Related]
19. Induction of innate immunity against herpes simplex virus type 2 infection via local delivery of Toll-like receptor ligands correlates with beta interferon production.
Gill N; Deacon PM; Lichty B; Mossman KL; Ashkar AA
J Virol; 2006 Oct; 80(20):9943-50. PubMed ID: 17005672
[TBL] [Abstract][Full Text] [Related]
20. An update on short-course episodic and prevention therapies for herpes genitalis.
Corey L; Bodsworth N; Mindel A; Patel R; Schacker T; Stanberry L
Herpes; 2007 Jun; 14 Suppl 1():5A-11A. PubMed ID: 17877886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
